MedTrace Logo

Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome （IBS)

NCT05113888 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-11-09

No results posted yet for this study

Summary

The purpose of this study are as follows: 1) To evaluate the efficacy and safety of Qizhi Weitong granules in the treatment of diarrhea-type irritable bowel syndrome (IBS-D);2) To explore the dosage of Qizhi Weitong Granulesin treatment of IBS-D.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

Qizhi weitong granules(High）

take orally before meals, 1 bag each time, 3 times a day.

DRUG

Qizhi weitong granules(Low）

take orally before meals, 1 bag each time, 3 times a day.

DRUG

Placebo

take orally before meals, 1 bag each time, 3 times a day.

Sponsors & Collaborators

  • China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-08-31
Completion
2022-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05113888 on ClinicalTrials.gov